PharmaCyte Biotech develops cancer cell therapies using its Cell-in-a-Box encapsulation technology, based in Las Vegas. It last closed at $5.39 on Nov 17, down 5.11% on the day. PMCB reports earnings on Wed, Dec 16, 2026.
PMCB · as of the Nov 17 close · updated after every close
Uptrend, overbought
The stock is 78% above its 20 day and 87% above its 50 day average. It is 87% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 80), overbought. The nearest support is the Pivot S1 at $5.37, and the nearest resistance the Pivot at $5.41.
Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 11.7%/day
Key levels
$8.1752 week high+51.6%
$5.43Pivot R1+0.7%
$5.41Pivot+0.4%
$5.39Last close
$5.37Pivot S1−0.4%
$1.2020 day average−77.7%
$0.7250 day average−86.6%
$0.71Swing low (Jun 22)−86.8%
$0.70200 day average−87.0%
$0.66100 day average−87.8%
$0.2552 week low−95.4%
Indicators
RSI (14)
79.81
Overbought above 70
Overbought
MACD
1.03
Above its signal line
Bullish
Stochastic
72.1
Middle of its range
Neutral
ADX (14)
31.3
Trending up
Williams %R
-35.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
188.0
Oversold below −100, overbought above 100
Overbought
Rate of change
+1484.8%
Change over 10 sessions
Bullish
ATR (14)
$0.63
Typical daily range, 11.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend, overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 13.2%/day
Key levels
$8.1752 week high+51.6%
$5.43Pivot R1+0.7%
$5.41Pivot+0.4%
$5.39Last close
$5.37Pivot S1−0.4%
$1.2020 day average−77.7%
$0.7250 day average−86.6%
$0.71Swing low (Jun 22)−86.8%
$0.70200 day average−87.0%
$0.66100 day average−87.8%
$0.2552 week low−95.4%
Indicators
RSI (14)
77.86
Overbought above 70
Overbought
MACD
0.70
Above its signal line
Bullish
Stochastic
55.5
Middle of its range
Neutral
ADX (14)
39.3
Trending up
Williams %R
-35.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
360.4
Oversold below −100, overbought above 100
Overbought
Rate of change
+1097.3%
Change over 10 sessions
Bullish
ATR (14)
$0.71
Typical daily range, 13.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PMCB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PMCB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PMCB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PMCB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMCB is in one of them and how their past PMCB trades turned out.
PharmaCyte Biotech is a biotechnology company based in Las Vegas, Nevada, that develops cell therapies for cancer. Its Cell-in-a-Box technology places genetically engineered live human cells inside small capsules made mostly of cellulose, which are positioned near a tumor. Its main product candidate, CypCaps, is being developed for patients with locally advanced pancreatic cancer. Spending on these development programs has been reduced while the company reviews them.